Full Prescribing Info
Citicoline sodium.
Each capsule contains: Citicoline (as Sodium) 500 mg.
Each Film-Coated tablet contains: Citicoline (as Sodium) 1 g.
Pharmacology: Citicoline is a derivative of choline and cytidine that is involved in the biosynthesis of lecithin. It is claimed to increase blood flow and oxygen consumption in the brain and has been given in the treatment of cerebrovascular disorders, Parkinsonism, and head injury. Citicoline is an interneuronal communication enhancer. It increases the neurotransmission levels because it favors the synthesis and production speed of dopamine in the striatum acting then as a dopaminergic agonist thru the inhibition of tyrosine-hydroxylase.
Citicoline acts as a presynaptic cholinergic agent which favors the synthesis of acetylcholine. It also decreases the release of serotonin.
Citicoline makes the neurons more active, causing the astrocytes to loosen their grip on the capillaries, thus improving microcirculation. By virtue of this action, Citicoline has an indirect effect on microcirculation. It has the ability to slightly increase cerebral blood flow and exerts an anti-aggregation effect on platelets.
Pharmacodynamics: When administered orally, it is absorbed almost completely and its bioavailability is approximately the same when administered intravenously. Once absorbed, the cytidine and choline disperse widely throughout the body, cross the blood brain barrier, and reach the central nervous system (CNS), where they are incorporated into the phospholipid fraction of the cellular membrane and microsomes.
The concept that administration of exogenous Citicoline can augment the synthesis of neural membrane phospholipid is attractive, because accelerated replacement or repair plays a critical role in maintaining the healthy function of numerous physiological processes. It has shown therapeutic efficacy in a variety of diseases in which membrane disorder, dysfunction, or degeneration result in cellular and tissue ischemia and necrosis.
In the treatment of patients with acute ischemic cerebral vascular disease. Citicoline accelerates recovery of consciousness and motor deficit, achieves a better final outcome, and facilitates rehabilitation of these patients. The other major indication of Citicoline is for the treatment of senile cognitive impairment, either secondary to degenerative diseases (e.g Alzheimer disease) or to chronic cerebral vascular disease. In patient with chronic cerebral ischemia, Citicoline improves scores in cognitive rating scales, while in patients with senile dementia of the Alzheimer type it stops the course of the disease, and neuroendocrine, neuroimmunomodulatory, and neurophysiological benefits have been reported. Citicoline has also been shown to be effective in Parkinson disease, drug addictions, and alcoholism, as well as in amblyopia and glaucoma.
Dosage/Direction for Use
Citicoline 500 mg capsule once or twice a day or as prescribed by the physician.
Citicoline 1 g Film-Coated tablet once a day or as prescribed by the physician.
Must not be administered to patients with hypertonia of the parasympathetic.
Special Precautions
Citicoline should be used with caution in patients with acute, severe and progressive disturbance of consciousness, administration with hemostatics, intracranial pressure relieving drugs or use measures to keep body temperature low.
Adverse Reactions
Increase parasympathetic effects, fleeting and discrete hypotensor effect.
Seek medical attention immediately at the first sign of any adverse drug reaction.
Drug Interactions
Citicoline potentiates the effects of L-Dopa.
It must not be administered with meclofenoxate (clophenoxate).
Store at temperatures not exceeding 30°C.
MIMS Class
Nootropics & Neurotonics/Neurotrophics
ATC Classification
N06BX06 - citicoline ; Belongs to the class of other psychostimulants and nootropics.
Zynerva cap 500 mg
Zynerva FC tab 1 g
30's (P2,250/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in